2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11D.08 Tislelizumab in Combination with Anlotinib as First-Line Treatment for Advanced Pulmonary Sarcomatoid Carcinoma: A Phase II Study

P4.11D.08 Tislelizumab in Combination with Anlotinib as First-Line Treatment for Advanced Pulmonary Sarcomatoid Carcinoma: A Phase II Study

Back to course

Pdf Summary

A Phase II, single-arm clinical study evaluated the efficacy and safety of a combined treatment of Tislelizumab and Anlotinib for advanced pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer (NSCLC) with poor prognosis. The study enrolled 21 patients from August 2021 to December 2023, with a median age of 71 years, predominantly male (76.2%), and varied ECOG scores indicating different performance statuses.<br /><br />The trial assessed the objective response rate (ORR), a primary endpoint, alongside secondary endpoints of progression-free survival (PFS), overall survival (OS), and safety. Results showed an ORR of 52.4% and a disease control rate (DCR) of 85.7%, indicating the regimen met its primary efficacy endpoint. Patients experienced partial response in 47.6% of cases, stable disease in 33.3%, and complete response in 4.8%.<br /><br />The median PFS was 8.0 months, while the OS was 13.4 months, suggesting promising survival outcomes for this patient cohort. However, the treatment was associated with significant adverse events, with immune-related toxicities reported in 52.4% of patients. Grade 3 or higher treatment-related adverse events occurred in 23.8% of the participants, including cases of immune-mediated hepatitis, pneumonia, and one instance of grade 4 myocarditis. No treatment-related deaths were reported.<br /><br />The study concluded that Tislelizumab combined with Anlotinib is a safe and effective first-line treatment for patients with PSC, although larger trials are necessary for further confirmation. The research was funded by the National Natural Science Foundation of China and the Natural Science Foundation of Jiangxi Province.

Asset Subtitle

Zhimin Zeng

Meta Tag

Speaker Zhimin Zeng

Topic Metastatic NSCLC – Immunotherapy

Keywords

Phase II clinical study

Tislelizumab

Anlotinib

pulmonary sarcomatoid carcinoma

non-small cell lung cancer

objective response rate

progression-free survival

immune-related toxicities

National Natural Science Foundation of China

Natural Science Foundation of Jiangxi Province